Nasdaq · Healthcare
Royalty Pharma plc (RPRX)
As-reported financials and recent SEC filings for Royalty Pharma plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.38B
Net income
$770.9M
Net margin
32.4%
Diluted EPS
$1.78
ROE
7.9%
P/E (TTM)
29.6×
Market cap
$32.38B
Debt / equity
0.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Gross profit | — | — | — | — | — |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M |
| Diluted EPS | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →1442026-06-24
View on EDGAR →1442026-06-23
View on EDGAR →1442026-06-23
View on EDGAR →SCHEDULE 13D/A2026-06-16
View on EDGAR →42026-06-08
View on EDGAR →42026-06-08
View on EDGAR →Go deeper on RPRX
Search Royalty Pharma plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.